G1 Therapeutics to Release Third Quarter 2022 Financial

RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2022 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology firm, will host a webcast and convention name to present a company and monetary replace for the third quarter of 2022 on Wednesday, November 2, 2022, at 8:30 a.m. ET.

Please be aware that there’s a new course of to entry the decision by way of phone. To register and obtain a dial in quantity and distinctive PIN to entry the reside convention name, please comply with this hyperlink to register on-line. While not required, it is strongly recommended that you just be part of 10 minutes prior to the beginning of the occasion. A reside and archived webcast might be out there on the Events & Presentations web page of the corporate’s web site: www.g1therapeutics.com. The webcast might be archived on the identical web page for 90 days following the occasion.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical firm targeted on the event and commercialization of subsequent era therapies that enhance the lives of these affected by most cancers, together with the Company’s first business product, COSELA® (trilaciclib). G1 has a deep scientific pipeline and is executing a tumor-agnostic growth plan evaluating COSELA in quite a lot of strong tumors, together with colorectal, breast, lung, and bladder cancers. G1 Therapeutics is predicated in Research Triangle Park, N.C. For further data, please go to www.g1therapeutics.com and comply with us on Twitter @G1Therapeutics.

G1 Therapeutics® and the G1 Therapeutics emblem and COSELA^® and the COSELA emblem are emblems of G1 Therapeutics, Inc.

G1 Therapeutics Contacts:

Will Roberts
Vice President
Investor Relations and Corporate Communications
(919) 907-1944
[email protected]

Rebecca Levine
Director, Corporate Communications and Public Relations
(919) 667-8711
[email protected]